Cargando…

Management and characteristics of patients suffering from Clostridiodes difficile infection in primary care

BACKGROUND: Clostridioides difficile infection (CDI) is rising and increases patient healthcare costs due to extended hospitalisation, tests and medications. Management of CDI in French primary care is poorly reported. OBJECTIVES: To characterise patients suffering from CDI, managed in primary care...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klezovich-Bénard, Maria, Bouchand, Frédérique, Rouveix, Elisabeth, Goossens, Pierre L., Davido, Benjamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583832/ https://www.ncbi.nlm.nih.gov/pubmed/34755587 http://dx.doi.org/10.1080/13814788.2021.1998447

Ejemplares similares

670. Clinical Characteristics and Outcomes in Patients with Healthcare Facility-Onset Clostridiodes difficile Infections
por: Joshi, Seema, et al.
Publicado: (2023)

Risk for Clostridiodes difficile Infection among Older Adults with Cancer
por: Kamboj, Mini, et al.
Publicado: (2019)

972. Asymptomatic Carriage of Clostridiodes difficile and Risk of Subsequent Infection
por: Espiritu, Katrina, et al.
Publicado: (2018)

A Predictive Model to Identify Complicated Clostridiodes difficile Infection
por: Berinstein, Jeffrey A, et al.
Publicado: (2023)

Updates and Opinions in Diagnosis and Treatment of Clostridiodes difficile in Pediatrics
por: Malhotra, Sanchi, et al.
Publicado: (2021)

Descriptive Study of Gut Microbiota in Infected and Colonized Subjects by Clostridiodes difficile
por: Sánchez-Pellicer, Pedro, et al.
Publicado: (2021)

779. Clostridiodes difficile: Is it time for surveillance! Cost-benefit analysis
por: Yassin, Mohamed, et al.
Publicado: (2020)

753. Impact of COVID-19 on Healthcare Facility-Onset Clostridiodes difficile Infection
por: Suleyman, Geehan, et al.
Publicado: (2021)

749. A Nurse-Driven Protocol for Early Detection of Clostridiodes difficile Infections
por: Beckman, Shannon, et al.
Publicado: (2021)

The Association Between the Frequency of Interruptions in Antibiotic Exposure and the Risk of Health Care-Associated Clostridiodes difficile Infection
por: Song, Jiyoun, et al.
Publicado: (2020)

2424. Shedding of Viable Clostridiodes difficile in Patients Admitted to a Medical Intensive Care Unit
por: Young, Vincent B, et al.
Publicado: (2019)

The real efficacy of microbiota restoration following standard of care antimicrobial in patients with recurrent Clostridiodes difficile
por: Sehgal, Kanika, et al.
Publicado: (2023)

Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review
por: Gupta, Akshita, et al.
Publicado: (2021)

2393. Dimensions of Cumulative Antibiotic Exposure and Risk of Hospital Onset Clostridiodes Difficile
por: Song, Jiyoun, et al.
Publicado: (2019)

The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic
por: Mason, Clive S., et al.
Publicado: (2023)

708. Three Stages of Laboratory Stewardship in Improving Appropriate Clostridiodes Difficile Testing
por: Beckman, Shannon, et al.
Publicado: (2023)

In veteran outpatients, antibiotics remain significant risk factor for community-acquired Clostridiodes difficile infection
por: Akpoji, Ukwen, et al.
Publicado: (2022)

Evidence of within-facility patient–patient Clostridiodes difficile infection spread across diverse settings
por: Justice, Samuel, et al.
Publicado: (2022)

Two Groups of Cocirculating, Epidemic Clostridiodes difficile Strains Microdiversify through Different Mechanisms
por: Murillo, Tatiana, et al.
Publicado: (2018)

Clostridiodes difficile in COVID-19 Patients, Detroit, Michigan, USA, March–April 2020
por: Lakkasani, Saraswathi, et al.
Publicado: (2020)

2346. Cost Savings Associated with Implementation of Clinical Decision Support for Clostridiodes difficile Testing
por: Hoegg, Cindy L, et al.
Publicado: (2019)

Rate and predictors of 30-day readmission for clostridiodes difficile: a United States analysis
por: Kichloo, Asim, et al.
Publicado: (2022)

706. Effect of the Covid-19 Pandemic on Rates of Recurrent Clostridiodes difficile Infection in the Veterans Affairs System
por: Drekonja, Dimitri M, et al.
Publicado: (2021)

798. Metronidazole Exposure Prior to Clostridiodes difficile Infection (CDI) is a Risk Factor for Severe C. difficile Disease in Cancer Patients
por: Francisco, Denise Marie A, et al.
Publicado: (2020)

Rational design of a microbial consortium of mucosal sugar utilizers reduces Clostridiodes difficile colonization
por: Pereira, Fátima C., et al.
Publicado: (2020)

2379. It’s Getting Complicated: Outcomes of Clostridiodes difficile PCR Positive/Toxin-Negative Patients
por: Morillas, Jose A, et al.
Publicado: (2019)

747. Association of Clostridiodes difficile Infection Incidence With Renewed Vigor in Infection Prevention Practices With the Onset of the COVID-19 Pandemic
por: Khan, Ahmed A, et al.
Publicado: (2021)

2359. Prospective Feasibility Study for Novel Ultrasensitive Multiplexed Immunoassay for Clostridiodes difficile Toxins A and B
por: Watson, Lauren, et al.
Publicado: (2019)

Engineered Secretory Immunoglobulin A provides insights on antibody-based effector mechanisms targeting Clostridiodes difficile
por: Bharathkar, Sonya Kumar, et al.
Publicado: (2023)

675. The Fidaxomicin Cascade: Analysis of Success Rates and Barriers of Fidaxomicin Discharge Prescriptions for Inpatients Diagnosed with Clostridiodes Difficile
por: Cook, Ellen, et al.
Publicado: (2023)

2384. The Relationship Between Rifaxamin Use and the Prevalence of Clostridiodes difficile and Vancomycin-Resistant Enterococcus in Patients with Advanced Liver Disease
por: Alberto. De Jesus, Francisco, et al.
Publicado: (2019)

Clostridiodes difficile Treatment Guided by Polymerase Chain Reaction Stool Testing Does not Alter Outcomes for Patients With Inflammatory Bowel Disease
por: Chandrabos, Ceena, et al.
Publicado: (2021)

2422. Efficacy of Cefoxitin for the Treatment of Urinary Tract Infection (UTI) Due to ESBL-Producing E. coli and K. pneumoniae Isolates
por: Senard, Olivia, et al.
Publicado: (2018)

Efficacy of cefoxitin for the treatment of urinary tract infection due to extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates
por: Senard, Olivia, et al.
Publicado: (2018)

Identification of ADS024, a newly characterized strain of Bacillus velezensis with direct Clostridiodes difficile killing and toxin degradation bio-activities
por: O’Donnell, Michelle M., et al.
Publicado: (2022)

397. Oral Vancomycin Versus Fidaxomicin for Clostridiodes difficile: A Comparative Retrospective Evaluation across a Large, Multi-center Healthcare System
por: Roemer, Kaleb, et al.
Publicado: (2022)

Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time
por: Davido, Benjamin, et al.
Publicado: (2020)

Mechanisms of NK Cell-Macrophage Bacillus anthracis Crosstalk: A Balance between Stimulation by Spores and Differential Disruption by Toxins
por: Klezovich-Bénard, Maria, et al.
Publicado: (2012)

Subcutaneous Phaeohyphomycosis Due to Pyrenochaeta romeroi Mimicking a Synovial Cyst
por: Dinh, Aurélien, et al.
Publicado: (2016)

High prevalence of Clostridiodes diffiicle PCR ribotypes 001 and 126 in Iran
por: Baghani, Akram, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2rb49qr0pn59g0o1egan23m771